Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin (original) (raw)

Cancer Gene Therapy volume 13, pages 415–419 (2006)Cite this article

Abstract

The poor prognosis for patients with metastatic osteosarcoma (OS) indicates that new therapeutic options should be explored. Studies with adenoviral-mediated p53 gene transfer have been conducted in many cancer types including cervical, ovarian, prostatic and head and neck tumors. However, limited work has been carried out with pediatric cancers, including OS. Using three viral constructs containing cDNA for wild-type p53, mutant p53 (Cys135Ser) and lacZ, we studied the effect of adenoviral-mediated gene therapy in four OS cell lines: Saos-2 (p53−/−), HOS (R156P), KHOS/NP (R156P) and MNNG (R156P, F270L). We demonstrated that the virus efficiently enters the cells using the β_-galactosidase assay. Using the MTT assay, we have shown a dose-dependent decrease in cell viability 72 h post-treatment that occurs with Ad-wt_p53 but not with Ad-mut_p53_. We have also shown that treatment with Ad-wt_p53_ significantly increases sensitivity of the cell lines to cisplatin and doxorubicin, chemotherapeutic agents commonly used in the treatment of OS. Our results indicate that restoration of wt p53 function in OS cells provides a basis for novel approaches to treatment of this disease.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Link MP, Eilber F . Osteosarcoma. In: Pizzo PA, Poplack DG (eds.), Principles and Practice of Pediatric Oncology, 3rd edn. Lippincott-Raven: Philadelphia, 1997.
    Google Scholar
  2. Dorfman HD, Czerniak B . Bone cancers. Cancer 1995; 75(Suppl 1): 203–210.
    Article CAS Google Scholar
  3. Hahn M, Dormans JP . Primary bone malignancies in children. Curr Opin Pediatr 1996; 8: 71–74.
    Article CAS Google Scholar
  4. Kawashima H, Ogose A, Yoshizawa T, Kuwano R, Hotta T, Hatano H et al. Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: efficacy of adenoviral gene therapy for osteosarcoma. Cancer Sci 2003; 94: 70–75.
    Article CAS Google Scholar
  5. Yeh YA, Herenyiova M, Weber G . Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells. Life Sci 1995; 57: 1285–1292.
    Article CAS Google Scholar
  6. Chang EH, Pirollo KF, Bouker KB . Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today 2000; 6: 358–364.
    Article CAS Google Scholar
  7. Swisher SG, Roth JA . Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am 2002; 11: 521–535.
    Article Google Scholar
  8. Gu W, Ogose A, Kawashima H, Ito M, Ito T, Matsuba A et al. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res 2004; 10: 3831–3838.
    Article CAS Google Scholar
  9. Graat HC, Wuisman PI, van Beusechem VW, Carette JE, Gerritsen WR, Bras J et al. Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses. Clin Cancer Res 2005; 11: 2445–2447.
    Article CAS Google Scholar

Download references

Acknowledgements

HG is supported by funds from the Canadian Institutes of Health Research. MG, MK and NP were funded through studentships of the Ontario Student Opportunity Trust Fund – Hospital for Sick Children Foundation Student Scholarship Program. AN is supported by a Research Scientist award from the Kids Cancer Care Foundation of Alberta. This work was supported in part by a Seed Grant of the Research Institute, The Hospital for Sick Children, the Andrew Mizzoni Cancer Research Fund, and the Harry and Hanna Fisher Research Fund.

Author information

Author notes

  1. A Narendran
    Present address: Southern Alberta Children's Cancer Program, Alberta Children's Hospital, Calgary, Alberta, Canada

Authors and Affiliations

  1. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    H Ganjavi
  2. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    M Gee
  3. Division of Haematology-Oncology, Department of Paediatrics and Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada
    A Narendran, N Parkinson, M H Freedman & D Malkin
  4. Department of Surgery, DCH Regional Medical Center, Tuscaloosa, AL, USA
    M Krishnamoorthy

Authors

  1. H Ganjavi
  2. M Gee
  3. A Narendran
  4. N Parkinson
  5. M Krishnamoorthy
  6. M H Freedman
  7. D Malkin

Corresponding author

Correspondence toD Malkin.

Additional information

Conflict of interest statement

None declared.

Rights and permissions

About this article

Cite this article

Ganjavi, H., Gee, M., Narendran, A. et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.Cancer Gene Ther 13, 415–419 (2006). https://doi.org/10.1038/sj.cgt.7700909

Download citation

Keywords

This article is cited by